和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCM 和黄医药

休市中 08-23 16:00:00 EDT

17.26

-0.63

-3.52%

盘后17.26

+0.000.00%

16:00 EDT

最高17.74	最低16.98	成交量6.90万
今开17.53	昨收17.89	日振幅4.22%
总市值29.50亿	流通市值17.33亿	总股本1.71亿
成交额119.16万	换手率0.07%	流通股本1.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCM","market":"US","secType":"STK","nameCN":"和黄医药","latestPrice":17.26,"timestamp":1724443200000,"preClose":17.89,"halted":0,"volume":68956,"hourTrading":{"tag":"盘后","latestPrice":17.26,"preClose":17.26,"latestTime":"16:00 EDT","volume":492,"amount":8491.92,"timestamp":1724443209537},"delay":0,"floatShares":100406873,"shares":170888009,"eps":-0.245665,"marketStatus":"休市中","marketStatusCode":7,"change":-0.63,"latestTime":"08-23 16:00:00 EDT","open":17.53,"high":17.735,"low":16.98,"amount":1191578.160208,"amplitude":0.042202,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.245665,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724659200000},"adr":1,"listingDate":1458187200000,"adjPreClose":17.89,"adrRate":5,"postHourTrading":{"tag":"盘后","latestPrice":17.26,"preClose":17.26,"latestTime":"16:00 EDT","volume":492,"amount":8491.92,"timestamp":1724443209537},"volumeRatio":0.6821504804580392,"impliedVol":0.1498,"impliedVolPercentile":0.0198},"requestUrl":"/m/hq/s/HCM/wiki","defaultTab":"wiki","newsList":[{"id":"2461583741","title":"和黄医药(00013)下跌5.11%，报26.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461583741","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461583741?lang=zh_cn&edition=full","pubTime":"2024-08-23 10:16","pubTimestamp":1724379383,"startTime":"0","endTime":"0","summary":"8月23日，和黄医药(00013)盘中下跌5.11%，截至10:16，报26.9元/股，成交2827.2万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2024年中报，和黄医药营业总收入21.79亿元、净利润1.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/23101642640509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00013","HCM","BK4007","BK4585","BK1587","BK4531","BK1191","BK4588","BK1588"],"gpt_icon":0},{"id":"2461382705","title":"南向资金8月21日净买入和黄医药46.35万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2461382705","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461382705?lang=zh_cn&edition=full","pubTime":"2024-08-22 09:30","pubTimestamp":1724290205,"startTime":"0","endTime":"0","summary":"8月21日, 南向资金增持和黄医药46.35万股，连续3日增持。截止当日收盘，港股通共持有和黄医药16040.53万股，占流通股18.40%。港股通增持金额前五个股分别为建设银行、中国银行、工商银行、中国移动、快手-W。和黄医药近5个交易日下跌7.10%，港股通累计增持79.89万股；近20个交易日下跌4.25%，港股通累计增持394.16万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408220930099f45c76e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408220930099f45c76e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","HCM","00013","BK1587","BK1588"],"gpt_icon":0},{"id":"2460184700","title":"裁员求生难持久，医疗SaaS太美科技盈利难","url":"https://stock-news.laohu8.com/highlight/detail?id=2460184700","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460184700?lang=zh_cn&edition=full","pubTime":"2024-08-19 16:59","pubTimestamp":1724057987,"startTime":"0","endTime":"0","summary":"浙江太美医疗科技股份有限公司在科创板IPO失败后，转换赛道向港股IPO进军。7月30日，太美科技在港交所递交招股说明书。靠裁员挽救毛利率的太美科技，上市之路可能面临着诸多困难。早在2021年12月，太美科技就申报在科创板上市，并经历了三轮审核问询。2023年3月，上交所终止太美科技首次公开发行股票并在科创板上市审核。一旦有关部门要求补缴，太美科技还要支付一笔不小的费用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/238056","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","BK4007","BK4588","HCM","BK4531"],"gpt_icon":0},{"id":"2459212559","title":"和黄医药盘中异动 早盘快速跳水5.09%报18.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459212559","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459212559?lang=zh_cn&edition=full","pubTime":"2024-08-16 21:38","pubTimestamp":1723815514,"startTime":"0","endTime":"0","summary":"北京时间2024年08月16日21时38分，和黄医药股票出现异动，股价快速下跌5.09%。截至发稿，该股报18.65美元/股，成交量9989股，换手率0.01%，振幅1.58%。机构评级方面，在所有21家参与评级的机构中，90%的券商给予买入建议，10%的券商给予持有建议，无券商给予卖出建议。和黄医药股票所在的制药行业中，整体跌幅为0.25%。该公司经营两个可报告的肿瘤学/免疫学部门和其他风险投资部门。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816213835a1d4addf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816213835a1d4addf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4588","HCM","BK4585","BK4531"],"gpt_icon":0},{"id":"2459232840","title":"和黄医药(00013)下跌2.43%，报30.15元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459232840","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459232840?lang=zh_cn&edition=full","pubTime":"2024-08-16 10:13","pubTimestamp":1723774390,"startTime":"0","endTime":"0","summary":"8月16日，和黄医药(00013)盘中下跌2.43%，截至10:13，报30.15元/股，成交3.26亿元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2024年中报，和黄医药营业总收入21.79亿元、净利润1.84亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/16101342416358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4585","BK1191","BK1588","00013","BK4007","BK4531","HCM","BK1587","BK4588"],"gpt_icon":0},{"id":"2459427939","title":"和黄医药(US ADR)上涨2.04%，报19.5美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459427939","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459427939?lang=zh_cn&edition=full","pubTime":"2024-08-15 21:31","pubTimestamp":1723728688,"startTime":"0","endTime":"0","summary":"8月15日，和黄医药(US ADR)(HCM)开盘上涨2.04%，截至21:31，报19.5美元/股，成交4.47万美元。财务数据显示，截至2024年06月30日，和黄医药(US ADR)收入总额3.06亿美元，同比减少42.64%；归母净利润2580.1万美元，同比减少84.69%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/08/15213142408076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4585","BK1191","BK1588","00013","BK4007","BK4531","HCM","BK1587","BK4588"],"gpt_icon":0},{"id":"2459500492","title":"Paycor HCM 公司报告截至 6 月的季度业绩 - 盈利摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2459500492","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459500492?lang=zh_cn&edition=full","pubTime":"2024-08-15 14:09","pubTimestamp":1723702166,"startTime":"0","endTime":"0","summary":"   * Paycor HCM Inc   公布的截至6月底的季度调整后每股收益为11美分，高于去年同期的每股收益8美分。华尔街预期为每股收益 9 美分至 10 美分。* Paycor HCM Inc公布的本季度每股收益为亏损10美分。* 该公司当季亏损 1829 万美元。* Paycor HCM Inc 本季度股价下跌了 0.6%，今年迄今为止下跌了 41.5%。8月15日 - 预测变化   * 在过去三个月里，分析师的平均盈利预期上升了约 0.7%。华尔街对 Paycor HCM 公司 12 个月目标价的中位数为 18.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4539","BK4007","BK4023","BK4585","BK4531","PYCR","BK4588","HCM","BK4130","LU1169590202.USD"],"gpt_icon":0},{"id":"2459468542","title":"南向资金8月14日净买入和黄医药70.75万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2459468542","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459468542?lang=zh_cn&edition=full","pubTime":"2024-08-15 09:31","pubTimestamp":1723685484,"startTime":"0","endTime":"0","summary":"8月14日, 南向资金增持和黄医药70.75万股，连续3日增持。截止当日收盘，港股通共持有和黄医药15960.64万股，占流通股18.30%。和黄医药近5个交易日下跌3.19%，港股通累计增持111.35万股；近20个交易日上涨0.66%，港股通累计增持425.14万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408150939529f2c0c89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408150939529f2c0c89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCM","BK1587","BK1588","BK1191","00013"],"gpt_icon":0},{"id":"2459172283","title":"和黄医药盘中异动 早盘快速跳水5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459172283","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459172283?lang=zh_cn&edition=full","pubTime":"2024-08-14 21:30","pubTimestamp":1723642248,"startTime":"0","endTime":"0","summary":"北京时间2024年08月14日21时30分，和黄医药股票出现波动，股价急速下跌5.91%。截至发稿，该股报19.11美元/股，成交量1.27万股，换手率0.01%，振幅2.26%。和黄医药股票所在的制药行业中，整体涨幅为0.00%。其相关个股中，Im Cannabis Corp.、Incannex Healthcare Inc.、Evoke Pharma, Inc.涨幅较大，Fsd Pharma Inc.、大自然药业、Citius Oncology, Inc.较为活跃，换手率分别为8.86%、0.59%、0.37%，振幅较大的相关个股有Citius Oncology, Inc.、和黄医药、Fsd Pharma Inc.，振幅分别为4.06%、3.89%、2.90%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814213048ab5daeff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814213048ab5daeff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4588","HCM","BK4585","BK4531"],"gpt_icon":0},{"id":"2459413968","title":"Paycor HCM Inc    预计每股收益 9 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2459413968","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459413968?lang=zh_cn&edition=full","pubTime":"2024-08-13 05:47","pubTimestamp":1723499246,"startTime":"0","endTime":"0","summary":"   * Paycor HCM Inc    将于8月14日公布截至2024年6月30日的财报，预计季度收入将有所增长。* 根据LSEG的数据，17位分析师的平均预期显示，这家总部位于俄亥俄州辛辛那提市的公司的营收将从去年同期的1.4004亿美元增至1.6172亿美元，增幅为15.1%。* LSEG 分析师对 Paycor HCM 公司的平均预期为每股收益 9 美分。* 华尔街对 Paycor HCM Inc 的 12 个月目标价中位数为 18.00 美元，高于其最新收盘价 12.27 美元。8月12日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","PYCR"],"gpt_icon":0},{"id":"2458629505","title":"和黄医药午后涨超3% 机构指呋喹替尼海外销售超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2458629505","media":"新浪网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458629505?lang=zh_cn&edition=full","pubTime":"2024-08-12 13:05","pubTimestamp":1723439148,"startTime":"0","endTime":"0","summary":"和黄医药午后上涨3.21%，现报32.15港元，成交额4658.74万港元。中信建投指出，肿瘤及免疫业务综合收入持续增长，2024年上半年达到1.687亿美元，同比增长59%。呋喹替尼自23年11月在美国上市以来，表现强劲，销售额达到1.305亿美元。公司在推进全球化和扩展管线方面取得显著进展。下半年索乐匹尼布有望在国内获批，同时赛沃替尼有望于年底在美国提交新药上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081213432395917323&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081213432395917323&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCM","BK4007","BK4531","BK4588","BK4585"],"gpt_icon":0},{"id":"2458640826","title":"港股异动 | 和黄医药(00013)盘中涨超4% 呋喹替尼海外销售超预期 索乐匹尼布下半年有望获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2458640826","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458640826?lang=zh_cn&edition=full","pubTime":"2024-08-12 11:51","pubTimestamp":1723434680,"startTime":"0","endTime":"0","summary":"和黄医药(00013)盘中涨超4%，截至发稿，涨2.57%，报31.95港元，成交额4381.72万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240812/20240812115137_76056.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240812/20240812115137_76056.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","BK4531","BK1587","HCM","00013","BK1588","BK1191","BK4007","BK4588"],"gpt_icon":0},{"id":"2457679998","title":"【券商聚焦】财通证券维持和黄医药(00013)“增持”评级 料海外收入不断增长 成长确定性较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2457679998","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457679998?lang=zh_cn&edition=full","pubTime":"2024-08-07 15:24","pubTimestamp":1723015444,"startTime":"0","endTime":"0","summary":"金吾财讯 | 财通证券发研报指，和黄医药 2024H1总收入为3.1亿美元。该行表示，呋喹替尼在取得美国患者接受度的同时，于2023年11月16日迅速纳入2023年《NCCN结肠癌临床实践指南》和2023年《NCCN直肠癌临床实践指南》，亦获结直肠癌领域的另外数个主要治疗指南推荐。这些都将继续推动呋喹替尼在医生和患者中的认知度和使用。预计2025年实现盈利，公司海外收入不断增长，成长确定性较高，维持“增持”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZDJiMDMxMTQ0NzYwOTE1MWRjNWM4ZTAxY2ZiMjQwNjM2MTY3ODIyMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDJiMDMxMTQ0NzYwOTE1MWRjNWM4ZTAxY2ZiMjQwNjM2MTY3ODIyMw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1941847","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","00013","601108"],"gpt_icon":0},{"id":"2457007970","title":"成分股Castle Biosciences收涨13.96%，Exscientia ADR涨13.38%，和黄医药（HCM）涨10.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457007970","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457007970?lang=zh_cn&edition=full","pubTime":"2024-08-07 05:37","pubTimestamp":1722980247,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK4007","00013","LENZ","BK4588","EXAI","HCM","LXRX","BK4139","BK1587","BK1588","BK1191","TBPH","BK4531","BK4585"],"gpt_icon":0},{"id":"1126516992","title":"异动解读 | 和黄医药中期业绩超预期 呋喹替尼销售亮眼推动股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1126516992","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126516992?lang=zh_cn&edition=full","pubTime":"2024-08-06 21:34","pubTimestamp":1722951279,"startTime":"0","endTime":"0","summary":"和黄医药今日盘中大涨9.05%,报收于31.25港元,成交额高达1.14亿港元,引发市场广泛关注。其中,公司旗舰产品呋喹替尼在全球市场的销售表现亮眼,推动公司肿瘤及免疫药物收入同比大增59.6%至1.28亿美元,其中来自呋喹替尼在中国境外市场的销售收入达4300万美元,超出预期。多家机构对呋喹替尼的前景持乐观态度。华泰证券表示,呋喹替尼全球销售超预期,公司其他管线也取得切实进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM"],"gpt_icon":0},{"id":"2457847023","title":"和黄医药盘中异动 急速拉升8.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457847023","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457847023?lang=zh_cn&edition=full","pubTime":"2024-08-06 21:33","pubTimestamp":1722951191,"startTime":"0","endTime":"0","summary":"北京时间2024年08月06日21时33分，和黄医药股票出现波动，股价急速拉升8.94%。截至发稿，该股报19.86美元/股，成交量1.3172万股，换手率0.01%，振幅1.56%。和黄医药股票所在的制药行业中，整体涨幅为0.88%。呋喹替尼联合化疗针对2线胃癌适应症在上市审批中，今年有望国内获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408062133119f14369c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408062133119f14369c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","HCM","BK4588","BK4585","BK4531"],"gpt_icon":0},{"id":"1139660129","title":"异动解读 | 和黄医药盘前大涨7%,主因呋喹替尼销售超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1139660129","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139660129?lang=zh_cn&edition=full","pubTime":"2024-08-06 17:38","pubTimestamp":1722937099,"startTime":"0","endTime":"0","summary":"和黄医药(HCM)今日盘前大涨7.08%,引发市场关注。分析人士指出,主要原因是公司旗舰产品呋喹替尼在全球市场的销售表现超出预期。\n\n和黄医药此前发布的中期业绩显示,公司上半年实现盈利,现金储备充裕。其核心产品呋喹替尼在中国境外市场销售达4300万美元,推动公司肿瘤及免疫药物收入同比大增59.6%至1.28亿美元。\n\n多家机构看好呋喹替尼的前景。华泰证券表示,呋喹替尼全球销售超预期,公司其他管线也取得切实进展。招银国际则认为,考虑到呋喹替尼在美国的强劲销售势头,以及短期内在中国以外其他地区上市,上调公司目标价至35.61港元,维持\"买入\"评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM"],"gpt_icon":0},{"id":"2457909350","title":"【和黄医药(00013.HK)授出认股权计划项下的认股权及长期奖励计划项下的奖励】智通财经APP讯，和黄医药(00013.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457909350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457909350?lang=zh_cn&edition=full","pubTime":"2024-08-06 17:15","pubTimestamp":1722935732,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00013","HCM","BK4007","BK4585","BK1587","BK4531","BK1191","BK4588","BK1588"],"gpt_icon":0},{"id":"2457090958","title":"和黄医药(00013)授出认股权计划项下的认股权及长期奖励计划项下的奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2457090958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457090958?lang=zh_cn&edition=full","pubTime":"2024-08-06 17:15","pubTimestamp":1722935732,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，该公司已于2024年8月5日授出和黄医药于2015年采纳的认股权计划项下的认股权及和黄医药于2015年采纳的长期奖励计划项下的奖励。和黄医药向苏慰国(执行董事、首席执行官兼首席科学官)(即根据英国市场滥用条例履行管理职责的人士)授出其认股权计划项下的认股权，惟须受表现目标所规限;在承授人接纳的前提下，以供认购公司股本中合共140.58万股每股面值0.10美元的普通股。和黄医药向其1名雇员授出其认股权计划项下的认股权，在承授人接纳的前提下，以供认购公司股本中合共20万股普通股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1191","BK1588","00013","BK4007","BK4531","HCM","BK1587","BK4588"],"gpt_icon":0},{"id":"2457994060","title":"美股异动｜和黄医药盘前涨超7% 招银国际上调H股目标价并维持“买入”评级和黄医药(HCM.US)美股盘前涨超7%，报19.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457994060","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457994060?lang=zh_cn&edition=full","pubTime":"2024-08-06 16:16","pubTimestamp":1722932181,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4531","BK1191","BK1587","00013","BK4588","HCM","BK4007","BK1588","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0655},{"period":"1month","weight":-0.079},{"period":"3month","weight":-0.0785},{"period":"6month","weight":0.098},{"period":"1year","weight":0.2053},{"period":"ytd","weight":-0.0469}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0617},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2867},{"period":"ytd","weight":0.1827}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.04629},{"month":2,"riseRate":0.375,"avgChangeRate":-0.008286},{"month":3,"riseRate":0.375,"avgChangeRate":-0.005299},{"month":4,"riseRate":0.555556,"avgChangeRate":0.042359},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.070144},{"month":6,"riseRate":0.666667,"avgChangeRate":0.076759},{"month":7,"riseRate":0.555556,"avgChangeRate":0.038822},{"month":8,"riseRate":0.444444,"avgChangeRate":0.018975},{"month":9,"riseRate":0.375,"avgChangeRate":-0.043105},{"month":10,"riseRate":0.625,"avgChangeRate":0.00878},{"month":11,"riseRate":0.875,"avgChangeRate":0.147113},{"month":12,"riseRate":0.625,"avgChangeRate":0.007065}],"exchange":"NASDAQ","name":"和黄医药","nameEN":"Hutchison China Meditech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,HCM,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(HCM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(HCM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}